Literature DB >> 33916763

CRISPR Co-Editing Strategy for Scarless Homology-Directed Genome Editing.

Nina Reuven1, Julia Adler1, Nadav Myers1, Yosef Shaul1.   

Abstract

The clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 has revolutionized genome editing by providing a simple and robust means to cleave specific genomic sequences. However, introducing templated changes at the targeted site usually requires homology-directed repair (HDR), active in only a small subset of cells in culture. To enrich for HDR-dependent edited cells, we employed a co-editing strategy, editing a gene of interest (GOI) concomitantly with rescuing an endogenous pre-made temperature-sensitive (ts) mutation. By using the repair of the ts mutation as a selectable marker, the selection is "scarless" since editing restores the wild-type (wt) sequence. As proof of principle, we used HEK293 and HeLa cells with a ts mutation in the essential TAF1 gene. CRISPR co-editing of TAF1ts and a GOI resulted in up to 90% of the temperature-resistant cells bearing the desired mutation in the GOI. We used this system to insert large cassettes encoded by plasmid donors and smaller changes encoded by single-stranded oligonucleotide donors (ssODN). Of note, among the genes we edited was the introduction of a T35A mutation in the proteasome subunit PSMB6, which eliminates its caspase-like activity. The edited cells showed a specific reduction in this activity, demonstrating this system's utility in generating cell lines with biologically relevant mutations in endogenous genes. This approach offers a rapid, efficient, and scarless method for selecting genome-edited cells requiring HDR.

Entities:  

Keywords:  CRISPR/Cas9; co-editing; endogenous mutagenesis in cell lines; gene targeting; genome editing; scarless selection; temperature-sensitive cell lines

Year:  2021        PMID: 33916763     DOI: 10.3390/ijms22073741

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  3 in total

1.  Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism.

Authors:  Romano Strobelt; Julia Adler; Nir Paran; Yfat Yahalom-Ronen; Sharon Melamed; Boaz Politi; Ziv Shulman; Dominik Schmiedel; Yosef Shaul
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.379

2.  Evidence for a Hepatitis B Virus Short RNA Fragment Directly Targeting the Cellular RRM2 Gene.

Authors:  Karin Broennimann; Inna Ricardo-Lax; Julia Adler; Yosef Shaul
Journal:  Cells       Date:  2022-07-20       Impact factor: 7.666

Review 3.  Selecting for CRISPR-Edited Knock-In Cells.

Authors:  Nina Reuven; Yosef Shaul
Journal:  Int J Mol Sci       Date:  2022-10-07       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.